CTCA, Allscripts, NantHealth to launch clinical pathways, custom oncology treatment platform

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Cancer Treatment Centers of America, in collaboration with NantHealth and Allscripts, is implementing a custom technical solution that, for the first time, enables eviti, a NantHealth clinical decision support solution, access to clinical workflows in the Allscripts Sunrise electronic health record.

With integration of this clinical decision support solution, the Clinical Pathways program helps inform the cancer treatment process, without interrupting the physician’s clinical workflow.

The direct interface of the clinical operating system was built with the input of hundreds of oncologists across the nation and holds a comprehensive collection of evolving cancer care data. Clinical Pathways integrates the latest cancer research available, treatment regimens and complementary therapies into the Allscripts Sunrise EHR, giving oncologists the ability to create a curated list of care protocols at the point of care.

When the treatment platform is engaged, it provides:

  • Custom treatment regimens specific to the patient, their health and specific disease state

  • Comparisons between treatment options, including average market cost of delivery

  • Computer order entry with the tap of the screen – safe for the patient and efficient

  • Each treatment regimen recommended by eviti is mapped within the EHR to proprietary CTCA order sets that reflect an integrative approach to care delivery, which combines evidence-based clinical approaches with supportive therapies to meet each patient›s unique needs and optimize their quality of life while undergoing cancer treatment

  • Access to referenced up-to-date guidelines, response rates, adverse drug reactions and toxicity

  • Supporting clinical data

  • Real-time functionality

The integration of the eviti solution with Allscripts Sunrise EHR for Clinical Pathways allows physicians to retrieve information from an unbiased Evidence-Based Medical Library, which encompasses over 2,700 treatment regimens covering all cancers and cancer subtypes and all modalities.

Each regimen incorporates the level of evidence, expected clinical outcomes, treatment costs, toxicities and supporting literature. Once a regimen is selected, providers can launch directly into order entry through Allscripts’ open ability to integrate eviti regimens with Sunrise order sets.

Table of Contents

YOU MAY BE INTERESTED IN

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login